Quincy Bioscience, headquartered in Middleton, Wisconsin, has been recognized as the Best Biotechnology Firm of the Year – 2025 in the United States at the prestigious Global Health & Wellness Awards. The honor highlights the company’s leadership in developing innovative, nature-inspired solutions for the brain.

Founded in 2004 in collaboration with neuroscience expert Dr. James R. Moyer, Jr., Quincy Bioscience has built a foundation of research-driven innovation. Its flagship product, Prevagen®, is a dietary supplement formulated with the unique protein apoaequorin, originally discovered in jellyfish. Prevagen differs from traditional brain supplements by leveraging insights from the natural world, offering a science-driven approach.

According to NielsenIQ data, Prevagen has been the #1 selling brain supplement in the U.S. for more than a decade and is available in over 60,000 stores nationwide. Loyalty card data further confirms it as the most repurchased brain supplement in the country.

Quincy Bioscience prioritizes quality, safety, and transparency. Apoaequorin is produced in a cGMP-compliant facility, and the company is NSF International certified for its manufacturing standards. Research on apoaequorin has been published in peer-reviewed journals and presented at international neuroscience conferences. In compliance with FDA regulations, Prevagen is not intended to treat, cure, or prevent any disease.

By repurposing a bioluminescent protein from jellyfish, Quincy Bioscience demonstrates how nature-inspired innovation can drive safe, impactful biotechnology. The company credits its multidisciplinary team and rigorous scientific approach for its ongoing success and remains committed to merging science, safety, and the wisdom of nature in its mission to develop solutions for your brain.

Read the full feature on Global Performance Media Group.